Treatment of fibromyalgia with ubiquinone 10 and succinic acid

Abstract

A method is described for using a combination of ubiquinone 10 and succinic acid in the treatment of human patients afflicted with fibromyalgia to alleviate one or more symptoms associated with that disease state. Fibromyalgia positive patients treated buccally, sublingually or by oral ingestion administration of ubiquinone 10 and succinic acid enjoy a reduction in clinical symptoms of the disease.

What is claimed is:  
     
         1 . A method for treating a human patient suffering from fibromyalgia to produce a therapeutic response in said patient, said method comprising the step of administering to the patient ubiquinone 10 and succinic acid each at a dose of about 5 to about 500 mg/70 kg patient.  
     
     
         2 . The method of  claim 1  wherein the ubiquinone 10 and the succinic acid are each administered at a dose of about 50 to about 400 mg/70 kg patient.  
     
     
         3 . The method of  claim 1  wherein the ubiquinone 10 and the succinic acid are each administered at a dose of about 50 to about 200 mg/70 kg patient.  
     
     
         4 . The method of  claim 1  wherein the ubiquinone 10 and the succinic acid are formulated in combination in a pharmaceutically acceptable solid dosage form.  
     
     
         5 . The method of  claim 1  wherein the ubiquinone 10 and the succinic acid are formulated in combination in a pharmaceutically acceptable liquid dosage form.  
     
     
         6 . The method of  claim 4  wherein the solid dosage form is a saliva-soluble solid dosage form of said combination which is administered by being introduced into the mouth of the patient and held in the mouth for a period of time sufficient to dissolve in saliva in the patient's mouth to form a saliva solution comprising ubiquinone 10 and succinic acid.  
     
     
         7 . The method of  claim 6  wherein the solid dosage form is a lozenge.  
     
     
         8 . The method of  claim 1  wherein the ubiquinone 10 and the succinic acid are administered by oral ingestion.  
     
     
         9 . The method of  claim 1  wherein the ubiquinone 10 and the succinic acid are administered bucally.  
     
     
         10 . The method of  claim 1  wherein the ubiquinone 10 and the succinic acid are administered sublingually.  
     
     
         11 . The method of  claim 1  wherein the ubiquinone 10 and the succinic acid are administered parenterally.  
     
     
         12 . The method of  claim 1  wherein the dose of ubiquinone 10 and succinic acid is administered 1 to 4 times a day until the patient's symptoms of fibromyalgia have subsided.  
     
     
         13 . A pharmaceutical composition comprising therapeutically effective amounts of ubiquinone 10 and succinic acid as the active ingredients, and a pharmaceutically acceptable carrier therefor.  
     
     
         14 . The pharmaceutical composition of  claim 13  in the form of a liquid solution.  
     
     
         15 . The pharmaceutical composition of  claim 13  in the form of a capsule or caplet.  
     
     
         16 . The pharmaceutical composition of  claim 13  in the form of a tablet.  
     
     
         17 . The pharmaceutical composition of  claim 13  in gel-seal form.  
     
     
         18 . The pharmaceutical composition of  claim 13  in the form of a lozenge.  
     
     
         19 . The pharmaceutical composition of  claim 13  adapted for oral administration.  
     
     
         20 . The pharmaceutical composition of  claim 13  adapted for parenteral administration.